Mayo Clinic Oct 29 2025 Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two research teams, working collaboratively but using distinct approaches, found that "first-responder" immune cells known as myeloid cells can be manipulated to enhance the activity of tumor-killing T cells. The finding suggests that enhanced myeloid cells may boost certain immune checkpoint therapies, which are the standard of care